Sonnet BioTherapeutics (SONN) Competitors $5.90 +1.94 (+48.99%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.91 +0.01 (+0.19%) As of 09/12/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SONN vs. EXOZ, CNTB, IPA, ANIX, SRZN, MEIP, VIRI, ALTS, ORMP, and ANEBShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include eXoZymes (EXOZ), Connect Biopharma (CNTB), ImmunoPrecise Antibodies (IPA), Anixa Biosciences (ANIX), Surrozen (SRZN), MEI Pharma (MEIP), Virios Therapeutics (VIRI), ALT5 Sigma (ALTS), Oramed Pharmaceuticals (ORMP), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Its Competitors eXoZymes Connect Biopharma ImmunoPrecise Antibodies Anixa Biosciences Surrozen MEI Pharma Virios Therapeutics ALT5 Sigma Oramed Pharmaceuticals Anebulo Pharmaceuticals eXoZymes (NASDAQ:EXOZ) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings. Which has stronger earnings and valuation, EXOZ or SONN? eXoZymes has higher earnings, but lower revenue than Sonnet BioTherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeXoZymesN/AN/A-$5.86MN/AN/ASonnet BioTherapeutics$1M40.28-$7.44MN/AN/A Is EXOZ or SONN more profitable? eXoZymes' return on equity of -134.50% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets eXoZymesN/A -134.50% -81.63% Sonnet BioTherapeutics N/A -4,646.10%-342.21% Do analysts recommend EXOZ or SONN? Sonnet BioTherapeutics has a consensus target price of $20.00, suggesting a potential upside of 238.98%. Given Sonnet BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sonnet BioTherapeutics is more favorable than eXoZymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in EXOZ or SONN? 9.4% of Sonnet BioTherapeutics shares are held by institutional investors. 72.4% of eXoZymes shares are held by company insiders. Comparatively, 8.5% of Sonnet BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor EXOZ or SONN? In the previous week, eXoZymes and eXoZymes both had 1 articles in the media. eXoZymes' average media sentiment score of 1.91 equaled Sonnet BioTherapeutics'average media sentiment score. Company Overall Sentiment eXoZymes Very Positive Sonnet BioTherapeutics Very Positive SummarySonnet BioTherapeutics beats eXoZymes on 5 of the 9 factors compared between the two stocks. Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.04M$3.20B$5.87B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E RatioN/A21.1774.5225.93Price / Sales40.28480.02549.78198.13Price / CashN/A46.6837.5660.44Price / Book-8.319.6112.166.29Net Income-$7.44M-$53.29M$3.28B$270.77M7 Day Performance107.02%0.28%0.87%3.88%1 Month Performance49.37%5.73%4.96%4.88%1 Year Performance-9.01%10.52%60.74%26.01% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics2.8673 of 5 stars$5.90+49.0%$20.00+239.0%-7.9%$27.04M$1M0.0010Positive NewsGap UpHigh Trading VolumeEXOZeXoZymes1.2281 of 5 stars$12.00+0.3%N/AN/A$100.68M$70K0.0029Positive NewsCNTBConnect Biopharma3.8678 of 5 stars$1.77-1.7%$7.00+295.5%+30.0%$98.62M$26.03M0.00110Short Interest ↓IPAImmunoPrecise Antibodies2.6208 of 5 stars$2.10+8.5%$4.00+90.9%+222.8%$96.68M$17.59M-3.0880Upcoming EarningsGap UpANIXAnixa Biosciences2.9655 of 5 stars$3.02+1.2%$9.00+198.5%-11.7%$96.50M$210K-7.885News CoverageEarnings ReportAnalyst ForecastSRZNSurrozen2.986 of 5 stars$11.26-7.7%$38.50+241.9%+38.1%$96.50M$10.65M-0.7880Positive NewsMEIPMEI Pharma1.3182 of 5 stars$2.95-1.6%N/A+4.2%$96.48MN/A-0.62100Upcoming EarningsGap UpVIRIVirios TherapeuticsN/A$4.90-2.0%$5.00+2.0%+2,484.1%$94.36MN/A-18.155ALTSALT5 Sigma0.213 of 5 stars$4.24+2.6%N/A+84.1%$93.20M$22.26M0.00170Short Interest ↑ORMPOramed Pharmaceuticals0.8729 of 5 stars$2.27-1.3%N/A+2.1%$93.07M$1.34M-6.4910Positive NewsANEBAnebulo Pharmaceuticals2.4544 of 5 stars$2.22-6.7%$5.50+147.7%+13.4%$90.99MN/A-8.524News CoveragePositive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies eXoZymes Competitors Connect Biopharma Competitors ImmunoPrecise Antibodies Competitors Anixa Biosciences Competitors Surrozen Competitors MEI Pharma Competitors Virios Therapeutics Competitors ALT5 Sigma Competitors Oramed Pharmaceuticals Competitors Anebulo Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SONN) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SONN Stock Alerts